CTNNB1 and hepatocellular carcinoma: A retrospective analysis of genomic alterations of HCC patients undergoing immunotherapy revealed WNT1/CTNNB1 mutations to be associated with lower disease control rates (0% vs. 53%), shorter median progression free survival (PFS) (2.0 vs. 7.4 months), and shorter median OS [18,114].